Evofem Biosciences Inc
evofem.comEvofem Biosciences (NASDAQ: EVFM) is a pharmaceutical company that develops and commercializes prescription products for women's sexual and reproductive health. Revenue is generated through prescription drug sales, with products distributed through third-party contract manufacturers and external distribution networks rather than internal logistics. The company's commercial portfolio includes PHEXX, a vaginal pH modulator indicated for contraception, and SOLOSEC, a treatment for bacterial vaginosis and trichomoniasis. Evofem targets the U.S. women's health market, addressing conditions such as bacterial vaginosis, which affects an estimated 21 million women in the U.S. as of the FY2025 10-K filing. The company relies on two contract manufacturers, including DPT Laboratories Ltd., and delivers telehealth services through the PHEXX telehealth platform via third-party partners. A royalty obligation to Rush University on a single-digit percentage of gross receipts expired with the underlying patent; no royalties were recorded for the year ended December 31, 2025. The company carries convertible notes, derivative liabilities, and a stockholders' deficit as of December 31, 2025.
Products & Services
PHEXX: FDA-approved vaginal pH modulator indicated for contraception, also offered via the PHEXX telehealth platform. SOLOSEC: prescription treatment for bacterial vaginosis and trichomoniasis, featuring single-dose administration. Contraceptive educational chart for patients and healthcare providers, introduced in 2022.
Revenue Model
Prescription drug sales of PHEXX and SOLOSEC through the U.S. pharmaceutical channel, with pricing subject to pharmacy benefit manager contracts, government reimbursement programs, and insurer coverage requirements. No royalties payable to Rush University as of the year ended December 31, 2025 following patent expiration.
Customers & Markets
U.S. women ages 15 to 44 seeking contraception or treatment for bacterial vaginosis and related vaginal infections. Healthcare providers (HCPs) are the primary prescribing channel. End market addressable population for bacterial vaginosis cited at approximately 21 million U.S. women, roughly 29% of U.S. women ages 15 to 44, per the FY2025 10-K.
Geographic Exposure
United States only, based on filing disclosures. No international markets referenced in the excerpts.
Financial Snapshot
Loading...
